3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
45
Phase 1
20
Phase 3
13
Phase 1/2
11
Phase NA
2
Phase EARLY_PHASE1
2
Phase 4
1
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
1
Interventions
Cisplatin
30
Magnetic Resonance Spectroscopy
23
Carboplatin
23
pembrolizumab
21
Paclitaxel
20
Gemcitabine
19
Specimen Handling
16
Dexamethasone
15
Radiotherapy
14
Nivolumab
14
Drug Therapy
14
Doxorubicin
14
Bevacizumab
14
atezolizumab
13
Oxaliplatin
13
Cyclophosphamide
13
Radiation
11
Pemetrexed
11
Cytarabine
11
venetoclax
10
Vincristine
10
Prednisone
10
Docetaxel
10
Capecitabine
10
Trastuzumab
9
Temozolomide
8
Rituximab
8
Platinum
8
Ipilimumab
8
Fluorouracil
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Granulocyte Colony-Stimulating Factor
×
1 year
×
Clear all
NCT05139017
2026-06-04
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3
Recruiting
290 enrolled